Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 46 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 10392386

    JAK inhibitors containing a 4-membered heterocyclic amide

    Theravance Biopharma R&D IP, LLC · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  2. US 10391097

    Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors

    VTV THERAPEUTICS LLC · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  3. US 10391095

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  4. US 10391175

    BET bromodomain inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  5. US 10385080

    STAT6 inhibitors

    The Board of Regents of the University of Texas System · Granted Aug 20, 2019 · Expires Aug 15, 2039

    granted
  6. US 10385031

    Substituted piperazines as selective HDAC1,2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Aug 20, 2019 · Expires Aug 15, 2039

    granted
  7. US 10376510

    2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted
  8. US 10377772

    Macrocyclic LRRK2 kinase inhibitors

    Oncodesign SA · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted
  9. US 10376515

    Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activating enzyme ATG7

    Northwestern University · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted
  10. US 10370367

    IRAK inhibitors and method for making and using

    Rigel Pharmaceuticals, Inc. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  11. US 10370371

    Substituted pyrimidine Bmi-1 inhibitors

    PTC THERAPEUTICS, INC. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  12. US 10370360

    Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof

    The Board of Regents of the University of Texas System · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  13. US 10370333

    Sulfonamide compounds and uses as TNAP inhibitors

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  14. EP 3515433

    DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN

    BIAL PORTELA & Cª S A [PT] · Granted Jul 31, 2019 · Expires Jul 26, 2039

    granted
  15. US 10363261

    Enolase inhibitors and methods of treatment therewith

    The Board of Regents of the University of Texas System · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted
  16. US 10364238

    N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted
  17. US 10364258

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted
  18. US 10358421

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted
  19. US 10351532

    Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 16, 2019 · Expires Jul 11, 2039

    granted
  20. US 10344025

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted
  21. US 10344033

    2-aminoquinazoline derivatives as P70S6 kinase inhibitors

    SENTINEL ONCOLOGY LIMITED · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted
  22. US 10342786

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted
  23. US 10342764

    Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

    Oramed Ltd. · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted
  24. US 10335382

    Use of hydrogen sulfide synthesis inhibitors for cancer therapy

    The Board of Regents of the University of Texas System · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted